Revenue growth 16-18% for FY27
Overall company revenue expected to grow 16-18% in FY27, driven by high double-digit growth in Asia and Africa branded generics, mid-single-digit US growth, and India outperformance.
AJANTAPHARMA / guidance tracker
Keep management guidance in view.
Ajanta Pharma · forward-looking guidance across the available source record.
Research layer active
Guidance tracker
What management said would happen.
revenue
EBITDA margin ~27% ±1% for FY27
Management guided EBITDA margin of 27% with a variation of plus/minus 1%, factoring in investments, higher freight costs, and R&D spending.
Capex of ~₹400 crore in FY27
Capital expenditure expected to increase to around ₹400 crore, including ₹150 crore maintenance and ₹250 crore for capacity expansion.
Effective tax rate ~26-26.5% in FY27
Tax rate expected to increase as one manufacturing facility transitions out of exemption period.